Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive ...

Shares of Halozyme Therapeutics (HALO) and Jonhson & Johnson (JNJ) are under pressure on Tuesday after Leerink downgraded the stocks to Underperform and Market Perform, respectively. This comes after ...

Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

Q1 2025 Management View CEO Helen Torley emphasized the company’s focus on both organic and inorganic growth, with a strategy centered on expanding their ENHANZE drug delivery platform and continuing ...

Halozyme’s recurring revenue, product strength, and market resilience point to solid upside even with debt and tariff risks. Find out why HALO stock is a buy.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...

In this article, we are going to take a look at where Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands against other best cancer stocks to invest in for long-term gain. After cardiovascular ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a verbal warning into a lawsuit. In a lawsuit filed Thursday in a New ...